Suppr超能文献

以患者为中心的阿布昔替尼药代动力学微采样:使用 Tasso 装置进行多分析物检测桥接。

Patient-centric microsampling for abrocitinib pharmacokinetics: multiple-analytes assay bridging using Tasso device.

机构信息

Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA.

Pfizer Inc., 10555 Science Center Dr, San Diego, CA 92121, USA.

出版信息

Bioanalysis. 2024;16(15):825-834. doi: 10.1080/17576180.2024.2388939. Epub 2024 Sep 5.

Abstract

The feasibility of using Tasso devices (Tasso-SST and Tasso) collecting capillary blood samples for measuring abrocitinib and its metabolites were evaluated, and assay concordance established between capillary and venous blood samplings. Capillary serum and venous plasma concentrations were measured using their respective qualified and validated assays. Concentration and exposure comparisons were conducted for abrocitinib and its metabolites (M1, M2 and M4) to establish assay concordance. The correlation coefficient between capillary serum and venous plasma concentrations were >0.98 for all four analytes from three separate assays, and PK parameters (AUC and C) were compared and met bioequivalence criteria. These results demonstrate the feasibility of patient-centric microsampling device, such as Tasso, in future abrocitinib pediatric study.

摘要

评估了 Tasso 设备(Tasso-SST 和 Tasso)采集毛细血管血样测量阿布昔替尼及其代谢物的可行性,并建立了毛细血管血样和静脉血样之间的分析方法一致性。使用各自的合格和验证的分析方法测量毛细血管血清和静脉血浆浓度。比较阿布昔替尼及其代谢物(M1、M2 和 M4)的浓度和暴露量,以建立分析方法一致性。来自三个独立分析的所有四个分析物的毛细血管血清和静脉血浆浓度之间的相关系数均>0.98,并且 PK 参数(AUC 和 C)进行了比较并符合生物等效性标准。这些结果表明,在未来的阿布昔替尼儿科研究中,以患者为中心的微采样装置,如 Tasso,是可行的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4797/11415013/0953e0e0c5cb/IBIO_A_2388939_F0001_C.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验